Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer
1. OSTX has agreements for commercial manufacture of OST-HER2. 2. FDA meetings are imminent for OST-HER2's trial phase results. 3. OST-HER2 shows significant survival rate improvements in trials. 4. OSTX secured funding to support development and acquisition of new assets. 5. OSTX shares rose by 28.6% recently, reaching $2.58.